Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
http://www.priceseries.com/trade/CLSD-Clearside-Biomedical-Inc-stock-gains-54-percent-a-Trade-Record-by-priceSeries-2020123020210121.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments